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Abstract: With age, our cognitive skills and abilities decline. Maybe starting as an annoyance,
this decline can become a major impediment to normal daily life. Recent research shows that the
neurodegenerative disorders responsible for age associated cognitive dysfunction are mechanistically
linked to the state of the microvasculature in the brain. When the microvasculature does not function
properly, ischemia, hypoxia, oxidative stress and related pathologic processes ensue, further damaging
vascular and neural function. One of the most important and specialized functions of the brain
microvasculature is the blood–brain barrier (BBB), which controls the movement of molecules between
blood circulation and the brain parenchyma. In this review, we are focusing on tight junctions (TJs),
the multiprotein complexes that play an important role in establishing and maintaining barrier
function. After a short introduction of the cell types that modulate barrier function via intercellular
communication, we examine how age, age related pathologies and the aging of the immune system
affects TJs. Then, we review how the TJs are affected in age associated neurodegenerative disorders:
Alzheimer’s disease and Parkinson’s disease. Lastly, we summarize the TJ aspects of Huntington’s
disease and schizophrenia. Barrier dysfunction appears to be a common denominator in neurological
disorders, warranting detailed research into the molecular mechanisms behind it. Learning the
commonalities and differences in the pathomechanism of the BBB injury in different neurological
disorders will predictably lead to development of new therapeutics that improve our life as we age.
Keywords: aging; blood–brain barrier; tight junction
1. Introduction
Aging and age-related co-morbidities are rapidly increasing unresolved health and socio-economic
problems in developed countries. Decline of cognitive brain functions represents one of the main health
challenges of aging and includes vascular and neurodegenerative dementias such as Alzheimer’s or
Parkinson’s disease.
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The functional state of the central nervous system (CNS) is greatly dependent on the quality of the
vasculature. As the centuries old saying goes: “A man is as old as his arteries”. Today, especially for the
brain, this concept should be redefined: You are as old as your microvessels and capillaries [1]. There is
increasing evidence that the cerebral microvasculature and the neurovascular unit play a critical role
in age-related brain dysfunctions. The multitude of brain microvascular changes accompanied by
aging includes endothelial dysfunction, blood–brain barrier (BBB) breakdown, decrease in blood flow,
microhemorrhages, vessel rarefication and neurovascular uncoupling. In this review, our main focus is
the breakdown of the paracellular barrier and tight junctions.
2. Cells of the Neurovascular Unit (NVU)
The vasculature in the brain forms a functional unit with the surrounding neural tissue, thus
the term neurovascular unit was coined [2]. A functionally intact neurovascular unit (NVU) is a
prerequisite for the proper function of the CNS. The most important cellular components of the NVU are
cerebral endothelial cells, pericytes, astrocytic endfeet and neurons; however, other cellular elements
like microglia may also play a modulatory role. The main role of the NVU besides neurovascular
coupling is the formation of the BBB.
Cerebral endothelial cells (CECs) lining brain capillaries are considered the principal barrier
forming endothelial cells. They are interconnected by a continuous line of tight junctions and
characterized by a high number of mitochondria and low number of caveolae [3–5]. These characteristics
contribute to the formation of a paracellular and transcellular barrier.
Pericytes are localized in the duplication of the basement membrane covering the basal surface
of the endothelium. The estimates of pericyte coverage show large variations in the literature [6,7].
Pericytes can secrete a large number of substances that may influence endothelial function including
TGFβ, angiopoetin-1 or VEGF. It seems that the differentiation stage of pericytes determines their effect
on the endothelium as well [8]. The role of pericytes in the formation of the BBB is supported by the
finding that absence of pericytes leads to endothelial hyperplasia, abnormal vasculogenesis and an
increased BBB permeability [9,10].
Although the role of astrocytes in the formation of the physical barrier is limited, due to their
influence on cerebral endothelial cells they play an important role in the maintenance of the BBB [11].
The astrocytic endfeet ensheath the brain vasculature almost completely [12] and express the water
channel protein, aquaporin 4, which is suggested to play a crucial role in creating a bulk flow in the
brain parenchyma from arterioles towards venules. This flow was shown to contribute to the clearance
of extracellular proteins and metabolic waste products through the newly rediscovered glymphatic
system [13,14]. Despite much interest in the glymphatic system, some experimental results do not
support or even contradict its function [15]. Thus further refining of the glymphatic hypothesis is likely
necessary [16]. Nevertheless, the aquaporin 4 in astrocytic endfeet is indispensable to BBB function
as its knockout results in altered brain microvasculature and decreased water exchange through the
BBB [17], furthermore its subcellular distribution shows an age dependent depolarization accompanied
by decreased protein clearance [18].
The BBB is in the forefront of the defense line of the CNS and restricts the free movement of solutes
and cellular elements between the systemic circulation and neuronal tissue. The BBB is involved in the
pathogenesis of a large number of CNS disorders [19].
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Cell types comprising the NVU are in close communication in order to maintain physiologic
function and react to pathologies. Ligand-receptor type intercellular interactions and ion channels were
described early as pathways that coordinate the function of the cell types constituting the NVU [20].
An example of bidirectional information exchange is the role of CD146 in coordinating the development
of pericyte coverage on brain vasculature during early ontogenesis. At first CD146 is expressed by
endothelial cells but as pericyte coverage increases, CD146 expression shifts to pericytes where it
acts as a co-receptor of PDGFRβ. Endothelia attached pericytes down-regulate endothelial CD146
via TGFβ1 secretion, promoting BBB maturation [21]. Recently a growing body of evidence suggests
that extracellular vesicle—mainly exosome—mediated bidirectional communication coordinates key
functions of the NVU at the local and systemic level as well [22–25]. In a mouse model of spinal
cord injury, pericyte-derived exosomes improved microcirculation and protected barrier function [26].
In response to traumatic brain injury, the loss of pericytes and consequent impairment of crosstalk
among NVU cells causes barrier dysfunction, brain edema and leakage of cerebral vasculature. A recent
example of pericyte to endothelial cell communication in the retina is the circular RNA cPWWP2A
that is synthesized in pericytes and downregulates angiopoietin 1, occludin and sirtuin-1expression in
endothelial cells by sequestering miRNA-579 [27].
3. Brain Capillaries in Aging
With aging, the density of brain vasculature is decreased and cerebrovascular dysfunction
appears to precede and accompany cognitive dysfunction and neurodegeneration. Cerebrovascular
angiogenesis is decreased and cerebral blood flow is inhibited by anomalous blood vessels such as
tortuous arterioles and thick collagen deposits in the walls of veins and venules [28].
In most mammals, the capacity of CECs to divide is limited and endothelial cells are prone to
be senescent. Aging is associated with endothelial dysfunction, arterial stiffening and remodeling,
impaired angiogenesis, defective vascular repair and with an increasing prevalence of atherosclerosis [29].
In the aging brain cerebral blood flow declines and perfusion pressure either is constant or increases.
In Brown-Norway and Fisher 344/Brown-Norway rats that maintain a relatively consistent cortical
volume throughout life the densities of arterioles and arteriole-to-arteriole anastomoses on the cortical
surface was found to be decreased with age [30]. In a spontaneously hypertensive rat model, long
term hypertension was found to gradually destroy BBB, resulting in white matter lesions, one of
the most important pathological changes in vascular dementia [31]. At the capillary level, increased
capillary diameters and decreased capillary density paired with increased red blood cell velocities were
observed [28,32]. Some capillary density measurements in humans contradict these observations, as no
changes were observed in the intervascular distance on CD31 stained brain sections [33].
4. Junctional Proteins in Aging and Related Disorders
The paracellular barrier properties of CECs are determined by the tight junction (TJ), which are
composed of transmembrane proteins that control the transport across the intercellular space between
adjacent cells and cytoplasmic plaque. Claudin 5, member of the 27 strong claudin family, is primarily
responsible for controlling the paracellular transport of water and small molecules through capillary
vessel walls [34]. Other claudins may contribute to BBB function as well, though the isoforms present in
human and murine brain vessels is still under investigation [35,36]. Like claudins, MARVEL (MAL and
related proteins for vesicle trafficking and membrane link) proteins especially occludin play a role in
restricting paracellular transport and also regulate homeostasis and TJ organization [37–40]. The third
group of integral membrane proteins of the TJ belongs to the CTX (cortical thymocyte marker in
Xenopus) family within the immunoglobulin superfamily such as junctional adhesion molecules (JAM)
and coxsackie and adenovirus receptor (CAR). Integral membrane proteins of the TJ are coupled to
cytoplasmic plaque proteins that provide a platform for anchoring the junction to the cytoskeleton and
for interactions with signaling molecules. The main components of the cytoplasmic plaque are zonula
occludens (ZO) proteins [41–43].
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Junctional proteins are not restricted to the endothelial cells of the NVU. Recently, pericytic
occludin was described in a new role as a NADH oxidase enzyme and an important player in
BBB pericyte metabolism including the modulation of pericyte energy sharing with other NVU
components via intercellular transport of mitochondria and glucose [44]. Astrocytic occludin was
described two decades ago [45], and a recent report proposed a new role for it in RNA metabolism [46].
Astrocytic TJ, composed of claudin 1, 4 and JAM may also form in inflammation to control lymphocyte
segregation [47].
4.1. TJ in Aging and Aging Models
Limited data is available on what changes develop in the function of the BBB and the composition
and structure of endothelial TJs in the healthy aging human brain. In a meta-analysis of BBB permeability
studies, the barrier function was negatively impacted by age. Though there were some discrepancies,
paracellular permeability was generally increased in the aged human brain [48]. Multiple accelerated
aging animal models are available to complement this data, which we will discuss mainly together
with the appropriate aging associated disorders in later paragraphs. Literature data presented in this
chapter are summarized in Table 1. In the review we will include large molecule (e.g., albumin or
Evans blue albumin) permeability and blood component extravasation as well even though these are
not markers of TJ dysfunction but rather indicate transcellular transport or disruption of the vascular
wall respectively.
Int. J. Mol. Sci. 2019, 20, 5472 5 of 28
Table 1. Blood–brain barrier (BBB) function and junctional proteins in aging.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
BubR1 accelerated aging,
cell culture Discontinuous immunofluorescence for all three.
Baker et al., 2011
[49]
aged mouse and human
brain tissue
fragmented, weak
immunofluorescence, reduced
protein level.
fragmented, weak
immunofluorescence
increased 3kDa
dextran permeability
rescued by sirtuin-1
overexpression.
Stamatovic et al.,
2019 [50]
sirtuin-1 overexpression rescued by sirtuin-1overexpression
sirtuin-1 knockdown reduced claudin 5 mRNA andprotein increased
senescent female rats
Evans blue
extravasation,
hippocampus,
olfactory bulb
Bake and
Sohrabji 2004
[51]
senescent rats
weaker and discontinuous
immunofluorescence in
hippocampal vessels in senescent
compared to young female rats.
No change in middle aged vs.
young male rats
no change in
reproductive
senescent vs. young
female rats
age and gender
dependent IgG
extravasation, e.g.,
increased IgG
extravasation in
senescent female rat
thalamus
Bake et al., 2009
[52]
postmenopausal women altered distribution
ovariectomized rats unaffected increased connexin43redistribution Wilson et al.,
2008 [53]
+estrogen replacement rescued rescued
Pdgfrβ+/−, pericyte
deficient mice All three decreased.
Bell et al., 2010
[54]
24-month-old rats,
compared to 12-months-old
protein decreased,
mRNA unaffected
mRNA increased,
protein unaffected Mooradian et al.,
2003 [55]24-month-old rats,
compared to 3-months-old
protein decreased,
mRNA unaffected protein unaffected
mouse primary brain
microvessel endothelial
culture. disrupted
endothelial integrin/basal
lamina interaction
decreased increased Osada et al.,2011 [56]
integrin α5 knockout mice increased mRNA improved barrier resistant to MCAOinduced stroke
Roberts et al.,
2017 [57]
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Experimental results linking BBB dysfunction to declining cognitive function prompted the use of
modern in vivo imaging such as dynamic contrast enhanced magnetic resonance imaging to study
cerebrovascular permeability. A recent work revealed an age dependent BBB permeability increase in
the hippocampus of individuals without any cognitive impairment, which was exacerbated in the case
of mild cognitive impairment of Alzheimer’s, Huntington’s and multiple sclerosis patients [58].
Permeability changes are likely the result of decreased expression and disorganized localization
of TJ proteins. As shown in the BubR1 hypomorphic murine model of accelerated aging, claudin
5, occludin and ZO-1 expression of cortical and striatal microvessels were decreased in aged mice,
with reactive astrogliosis also apparent at the vessels. BubR1 is a key member of the mitotic checkpoint
that ensures accurate chromosome segregation [49]. In an experiment using cells isolated from BubR1
hypomorphic mice, aged CECs (co-cultured with pericytes) showed a discontinuous junctional staining
for claudin 5, occludin and ZO-1 and the presence of abnormal cells with smaller cytoplasm that are
highly immune-reactive for TJ proteins [59]. The BubR1 hypomorphic CECs also showed increased
number of spikes in the claudin 5 staining, reminiscent to those previously described as budding and
docking sites for claudin bearing vesicles [60].
Aged mouse and human brains both showed fragmented and weak claudin 5 and ZO-1 staining
in microvessels compared to healthy young controls, with an accompanying reduction of claudin
5 protein expression. BBB permeability to 3 kDa dextran was also increased in aged mice. Both claudin
5 levels and BBB function were rescued in transgenic mice overexpressing sirtuin-1, a NAD-dependent
deacetylase, while inducible, endothelial-specific knockdown of sirtuin-1 increased barrier permeability
and reduced claudin 5 mRNA and protein levels [50]. These results add a novel mode in which
sirtuin-1 affects longevity and neurological disorders by maintaining BBB integrity [61,62].
Barrier function of the cerebral vasculature was shown to be under the control of estrogen [63].
Thus, a potential influence of the age-dependent decline of estrogen levels on BBB integrity in
postmenopausal women or reproductive senescent female animals appeared plausible. In this context,
Bake and Sohrabji [51] showed enhanced extravasation of Evans Blue-albumin in the hippocampus and
olfactory bulb of reproductive senescent female rats. Moreover, the localization of the tight junction
protein claudin 5 in hippocampal microvessels was affected in senescent female rats compared to young
adult ones. In case of human brain microvessels, disrupted distribution and poor junctional localization
of claudin 5 was altered in postmenopausal women, in contrast to premenopausal women [52].
Further confirmation to suggest that reproductive hormones regulate BBB permeability came from
studies with ovariectomized rats [53]. While expression of ZO-1 was unaffected, redistribution and
increased expression of connexin-43 was observed following ovariectomy. Estrogen replacement
to young (4 months old) ovariectomized rats restored BBB function, while reproductive senescent
animals did not benefit from estrogen treatment or even showed increased BBB permeability in the
hippocampus [53].
Further evidence of age-related junctional alterations at the BBB came from a study showing
that the cerebral occludin protein content in total cerebral tissue extracts from 24-month-old rats was
significantly reduced compared to 12-month-old or 3-month-old male rats without a corresponding
change in occludin mRNA. ZO-1 protein levels were found to be unchanged while ZO-1 mRNA was
significantly increased in 24-month-old rats compared to 3-month-olds [55].
By using transmission electron microscopy, a decline in the pericytic coverage of aged capillaries
has been described over thirty years ago [64]. Beyond the assumption that the age-dependent loss
of pericytes decreases the ability of the BBB to compensate for transient leaks, there is evidence
that pericytes regulate the expression of TJ/BBB-specific proteins in microvascular endothelial cells.
A comparison of claudin 5, ZO-1 and occludin expression in 6–8 month old Pdgfrβ+/− mice has
revealed significant reductions of protein expression in pericyte-deficient mice compared to controls [54].
Therefore, it is likely that aging-associated TJ dysregulation may be partly the consequence of
pericyte loss.
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Integrins are heterodimeric proteins that anchor cells to the extracellular matrix and are involved in
ligand dependent bidirectional signaling between the cell and its environment thus playing important
roles in all cell functions. Researchers have found connections between integrins and aging [65,66]
and neurological disorders [67]. Disruption of cerebral endothelial integrin interaction with the basal
lamina lead to decreased claudin 5 levels and BBB integrity [56]. Recently, integrin α5 knockout mice
were found resistant to transient middle cerebral artery occlusion (MCAO) induced ischemic stroke
with a small initial infarct volume that disappeared within 3 days. The α5 knockout animals showed
improved barrier function and higher claudin 5 mRNA levels compared to controls [57].
CTX family proteins have not been directly linked to aging; however, some play important
roles in the brain development and function or tumorigenesis and invasiveness. JAM-A in CECs
undergoes subcellular relocalization in response to inflammatory stimuli [68] and its levels are reduced
in response to brain injury [20]. JAM3 was found to be essential for BBB integrity and for normal
lens development in humans. Homozygous mutations of JAM3 in humans led to brain hemorrhage
and brain calcification [69], the latter being somewhat similar to calcification in the basal ganglia in
occludin knockout mice [70]. Brain endothelial function of CAR is scarcely known. However, it was
found to play key roles in neurons in synapse development in the postnatal and adult brain and its
loss contributes to cognitive defects [71,72].
4.2. Brain Endothelial TJ in Ischemic Injury
In the healthy brain, practically every neuron has a capillary running next to it. With the rarefaction
of capillaries in aging brain, the ability to maintain homogeneous flow during periods of localized
ischemia is reduced. Hypoxia and reoxygenation are important components of many disorders that
affect the central nervous system, including stroke and dementia [73–75]. The incidence of stroke is
increased with age and the prognosis of elderly stroke patients is unfavorable compared to young
adults [76,77]. Literature data regarding TJs presented in this chapter are summarized in Table 2.
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Table 2. BBB function and junctional proteins in age related disorders, ischemic injury and immune system.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
hypoxia, 8% O2, mouse, brain
lysate unaffected
decreased protein levels unchanged protein levels Na-fluorescein
leakage increased
MMP and VEGF
dependence
Bauer et al.,
2010 [78]disrupted immunofluorescence for both
hypoxia in primary bovine brain
microvessel endothelial culture
membrane localization
perturbed
ZO2 membrane
localization perturbed,
ZO1 and ZO2 diffuse
cytosolic staining
sucrose permeability
increased
actin stress fibers,
increased actin
protein
Mark and Davis
2002 [79]
H2O2 ROS unaffected
phosphorylation change,
degradation TEER increase Lischper et al.,
2010 [80]
+GM6001 rescues degradation does not rescue
hypoxia/reoxygenation modeled
by DMNQ treatment of primary
mouse brain microvessel
endothelial culture
protein decreased Krizbai et al.,2005 [81]
hypoxia in bEND.3 altered localization,decreased protein increased
Koto et al., 2007
[82]
reactive oxygen species altered localization, decreased protein for both xanthine oxidase and100 µM hypoxanthine
Schreibelt et al.,
2007. [83]
MCAO, 12 months vs. 2 months
old mice
decrease in both age
groups, after 3 days
less protein in old
compared to young
decrease in both age
groups, after 1 and 3 days
less protein in old
larger Evans blue
extravasation in old
with stroke
Shen et al., 2019
[84]
young adult rats
hypoxia/reoxygenation phosphorylation no change in protein increased
Witt et al., 2003
[85]
young adult rats
hypoxia/reoxygenation disrupted Lochhead et al.,
2010 [73]as above + free radical scavenger
tempol rescued
young adult rats
hypoxia/reoxygenation
disrupted localization,
slightly increase
membrane fraction
disrupted localization,
slightly increase
membrane fraction
disrupted localization PKC-dependent focalBBB leakage
Willis et al., 2010
[86]
EGFP-Claudin 5 transgenic
mouse tMCAO
eGFP-claudin 5 no
change
no change no change Claudin 5 transgene
protein expression is
double of wild type.
Knowland et al.,
2014 [87]after 24–30 hours
after 48–58 hours eGFP-claudin 5 nonmembrane reduced reduced
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Table 2. Cont.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
600–950 g rats compared to
200–250 g rats degradation Kaur et al., 2011
[88]MCAO, both ages slightly increasedphosphorylation
tPA after reperfusion, only in old greatly increasedphosphorylation increased degradation
rat tMCAO +PP2 Src kinase
inhibitor, brain tissue
time dependent
decrease of claudin 5
protein and mRNA
was rescued by PP2
brain lysate protein decrease was significant
from 24, mRNA from 72 hours and persisted 7
days later, fibrinogen leakage from brain
coincided claudin 5 decrease and vas rescued
by PP2
Bai et al., 2014,
[89]
rat microsphere embolism,
capillary lysate
decreased amount,
increased
phosphorylation 6–72 h
after microsphere
injection
decreased amount albumin leakagestarting from 48 hours
Kago et al., 2006
[90]
rat microsphere embolism,
capillary lysate, +PP2
decreased amount and
increased
phosphorylation rescued
by PP2
albumin leakage
6-24h, rescued by PP2
Takenaga et al.,
2009 [91]
spontaneously hypertensive rats
tMCAO, brain sections
rapid reorganization in localization 3 h after
reperfusion + MMP2 activity at vessels. Protein
appeared in astrocytes.
Increased gelatinase activity 3 h after
reperfusion, rescued by MMP2 inhibition.
Yang et al., 2007,
Yang and
Rosenberg 2011
[92,93]brain lysate
decreased mRNA, degraded protein rescued by
BB-1101 MMP inhibitor
spontaneously hypertensive rats
tMCAO+GM6001 MMP inhibitor protein levels were rescued for all three
Yang et al., 2013
[94]
Primary human brain
microvascular endothelial
cells+PARP inhibition
increased protein levels for both Rom et al., 2015[95]
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Table 2. Cont.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
spontaneously hypertensive rats
tMCAO + mynocicline increased protein levels for all three
Yang et al., 2015
[96]
SRF, MRTF-A/-B knockdown
hemorrhagic stroke model,
whole brain tissue
claudin1, 3, 5 and 12
mRNA and claudin5
protein
downregulated
ZO-2 and ZO-3 mRNA
downregulated, ZO-1
unaffected
Weinl et al., 2015
[97]
bovine brain microvessel
endothelial cells +VEGF
distribution changed from membrane to cytoplasm,
protein levels increased
permeability increase,
resistance decrease
Wang et al., 2001
[98]
adenoviral expression of IL-1 in
VEGFA knockout mouse
VEGFA KO rescued protein expression of brain
microvessels in inflammatory lesions for both
Argaw et al.,
2012 [99]
EAE in VEGFA KO mouse
VEGFA KO rescued
protein expression of
brain microvessels in
inflammatory lesions
VEGFR2 blocking antibodies in
Cortical VEGF injected wild type
mice
rescued protein expression for both
eNOS inhibition or silencing in
human brain microvessel
endothelial cells
rescued protein
expression
24 months old mice compared to
3 months old, via fluorescence
activated cell sorting
significantly
decreased decreased IgG leakage
neurovascular
inflammation and
neuronal stress
Elahy et al., 2015
[100]
SAMP8 mice, 12 vs. 4 months
old, permeability
no change in albumin
permeability and
insulin uptake
Banks et al.,
2000 [101]
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In vitro studies of hypoxia and hypoxia followed by reoxygenation have revealed much of the
cellular mechanisms affected by ischemia in CECs. In oxidative stress, the interactions of occludin
with claudins or proteins of the ZO family are affected, directly influencing the formation and function
of the TJ. Oxidative stress downregulates occludin, reduces its specific membrane localization and
regulatory contribution to barrier tightness via multiple signaling pathways [102].
Significant disruptions were seen in the distribution pattern of occludin after hypoxia [78].
These changes were less apparent in posthypoxic reoxygenation, correlating to the increased protein
expression [79]. MCAO caused NADPH oxidase upregulation, ROS (reactive oxygen species)
generation, matrix metalloproteinase (MMP)-9 activation, and edema formation [103]. MMP activity in
oxidative stress increases paracellular permeability by occludin cleavage. However, applying the same
level of MMP activity without oxidative damage, neither is occludin cleaved nor BBB permeability is
increased [80]. In an opposite approach, normobaric hyperoxia protected the BBB, and the expression
and distribution of occludin against MMP-9–mediated effects in cerebral ischemia [103]. Thus occludin
plays a key role in the response of cellular barriers to redox changes and could be a redox sensor at
the TJs [104,105]. In a brain endothelial cell culture model of hypoxia/reoxygenation, ERK1/2 was
activated and the amount of occludin and barrier function decreased which was exacerbated by glucose
deprivation [81]. Hypoxia (1% O2) altered the location of claudin 5 in the plasma membrane and the
level of claudin 5 protein in bEND.3 cells, and these changes were accompanied by an increase in
BBB permeability. In vivo, claudin 5 was also significantly reduced under hypoxic conditions [82].
ROS-induced BBB disruption via the redistribution and decrease of claudin 5 and occludin levels was
paralleled by cytoskeleton rearrangements. This rearrangement was mediated by RhoA, PI3 kinase
and protein kinase B (PKB/Akt), and specific inhibitors prevented ROS-induced monocyte migration
across an in vitro model of the BBB [83].
The effect of age on the outcome of ischemic stroke was studied in murine distal MCAO
experiments, demonstrating an increased inflammatory reaction in 12 month old mice compared to
2 month olds based on IL-6 and IL-1β levels in the ischemic tissue. At the same time, there was an
increased number of CD68 immunoreactive cells, denoting phagocytosis and microglia activation
in peri-infarct tissue and the older mice suffered more severe BBB damage as well [84]. Similar BBB
permeability increase was observed in young adult rats after one hour of hypoxia (6% O2) followed
by 10 minutes of reoxygenation, which also lead to increased occludin phosphorylation without
significant changes in ZO-1 expression [85]. Disrupted occludin staining of brain endothelial cells in
rats was reversible by administration of ROS scavengers [73]. Another study under similar conditions
showed PKC-dependent focal BBB leakage and disrupted claudin 5, occludin and ZO-1 organization
at endothelial cell borders while the protein levels were slightly increased in the membrane fraction for
claudin 5 and occludin [86].
Functional changes of the BBB appear shortly after a hypoxic event, but structural TJ changes
develop much slower. Using an EGFP-claudin 5 transgenic mouse model, researchers demonstrated
a stepwise alteration of the BBB, leading to an increase in transcytosis followed by alterations of TJ
proteins, which undergo significant ultrastructural remodeling and localization changes starting at
48–58 h post tMCAO (transient middle cerebral artery occlusion) [87]. Early permeability increase
elicited by tissue plasminogen activator (tPA) during reperfusion in elderly rats was accompanied by
greatly increased claudin 5 phosphorylation while unphosphorylated claudin 5 decreased compared to
the contralateral side. MCAO treatment itself increased claudin 5 phosphorylation slightly. Occludin
protein level was decreased in elderly compared to young rats and further degradation was observed
in response to MCAO and tPA. These age-dependent differences in claudin 5 phosphorylation and
occludin degradation were inferred from redistribution of western blot bands [88].
In a multifocal cerebral ischemia model, Src kinase dependent tyrosine phosphorylation of
occludin was found to contribute to barrier disruption. Systemic inhibition of Src resulted in decreased
infarct size, decreased VEGF-A, rescuing claudin 5, occludin expression and barrier function [89–91].
Reperfusion experiments following 90-minute hypoxia in spontaneously hypertensive rats revealed
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MMP dependence of BBB leakage and the disruption of claudin 5 and occludin at the TJ in vivo.
Interestingly the TJ proteins from disrupted endothelial barrier appeared in adjacent astrocytes
underlining intercellular communication [92,93]. In vivo use of the MMP inhibitor GM6001 in rats as
an early treatment given at the time of MCAO increased the number of vessels and improved ZO-1,
occludin and claudin 5 expression in the infarct region 3 weeks after the ischemic injury [94].
In a sterile inflammation model induced by TNF-α in human primary brain microvascular
endothelial cells, PARP inhibition promoted BBB barrier function. Furthermore, PARP inhibition in
primary endothelial cells improved TEER and increased occludin and claudin 5 protein levels [95].
In spontaneously hypertensive rats that underwent MCAO, minocycline, an inhibitor of PARP-1 and
anti-inflammatory, anti-apoptotic and neuroprotective drug, significantly reduced the infarct size and
prevented tissue loss, improved perfusion, reduced BBB permeability and increased ZO-1, occludin
and claudin 5 protein levels. At the same time, increased MMP-2 and -3 were detected at four weeks,
at which time peri-infarct microglia showed M2 activation [96].
In a recent genetic model of intracerebral hemorrhagic stroke and vascular dementia, cerebral
small vessel disease symptoms were elicited by inducible knockdown of the transcription factor,
serum response factor (SRF) or its cofactors Myocardin Related Transcription Factor (MRTF-A/-B).
The microhemorrhagic phenotype observed in this model is attributed to loss of TJ components and is
specific for brain tissue. The authors demonstrated mRNA level decrease of claudin 1, 3, 5 and 12, as
well as ZO-2 and ZO-3, and significant loss of claudin 5 protein in isolated brain endothelial cells [97].
Exposing mice to normobaric hypoxia led to an increase in brain vascular permeability associated
with diminished expression of occludin and inhibition of VEGF attenuated vascular leakage [78].
This confirms the results of studies in primary brain endothelial cells in which VEGF decreased
occludin expression [98]. Astrocyte derived VEGF-A acts directly on brain microvasculature to
downregulate occludin protein and mRNA in vitro and in mouse models of experimental autoimmune
encephalomyelitis (EAE), inducing BBB permeability. In vivo inactivation of astrocytic VEGF-A
expression or systemic use of the eNOS inhibitor cavtratin rescued BBB function [99].
4.3. Involvement of Brain Barriers in Aging-Associated Alterations of Immune Functions
Brain barriers are important interfaces for neuroimmune communication and any disturbance may
inevitably result in CNS dysfunctions. Aging-associated alterations at the BBB and brain cerebrospinal
fluid (BCSF) barrier are thus considered to be one trigger for the development of cognitive impairment(s)
in the aged brain (reviewed in [106,107]). Literature data concerning TJs presented in this chapter can
be found at the end of Table 2.
While it is well established that migration of immune cells from the blood into the CNS parenchyma
is a process occurring in inflammatory and neurodegenerative state, accumulating evidence suggests
that immune cells also infiltrate the perivascular space of non-diseased brain, though at very low levels,
maintaining and contributing to the surveillance and homeostasis of the CNS (reviewed in [108–110]).
Less information exists concerning age-related immune cell trafficking across the BBB and BCSF,
obviously due to the fact that normal aging of the brain is usually accompanied by at least low level
inflammatory activity [111]. Leakage of IgG into the cerebral cortex and hippocampus of healthy aged
(24 months old) but not young (3 months old) mice were reported [100]. This leakage was accompanied
by a decrease in occludin and ZO-1 expression in cerebral endothelial cells but no signs of leukocyte
transmigration into the CNS.
A progressive age-related enhancement of TNFα-elicited T cell infiltration in brain parenchyma
and choroid plexus of mice was demonstrated by Xu et al. [112]. Further, Stichel and Luebbert [113]
reported on the presence of T cells and dendritic-like cells in mouse brain parenchyma at about 12
months of age, with numbers increasing during aging. T cells from aged mice were found to exhibit
increased expression of adhesion molecules, such as CD11a and CD49d, facilitating diapedesis [114]
and elevated ICAM1 expression was found in brain vasculature of aged human and mouse brains [115].
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The role of aging-associated T cell infiltration of the non-diseased brain is still unclear. Results from
single-cell RNA-sequencing and immunofluorescence staining of the subventricular zone from
young (3 month old) and old (28–29 months) mice suggest that T cells, expressing interferon-γ,
were clonally expanded and markedly enriched in the subventricular zone from old mice [116]. In vitro
studies have shown that T cells can inhibit the proliferation of neural stem cells in co-cultures in an
interferon-γ-dependent mechanism [116]. Thus, it may be assumed that interaction of T cells with
neural stem cells in neurogenic niches of old animals may contribute to the proliferative decline
of neural stem cells during aging. A distinct role of immune cells was demonstrated in increasing
cerebral vascular permeability [117]. Using a mouse model of CD8 T cell-mediated CNS vascular
permeability it was shown that CD8 T cells are capable of initiating BBB disruption in a non-apoptotic
perforin-dependent manner.
4.4. Alzheimer’s Disease (AD)
The blood–brain barrier contributes to the pathology and may play a causative role in the
development of the most common neurodegenerative disease aﬄicting the elderly population:
Alzheimer’s disease (AD). The involvement of the BBB happens through multiple mechanisms
such as barrier disruption, transporter dysfunction and secretion of neurotoxic substances [118,119].
Amyloid-β peptide (Aβ), the main component of senile plaques in the AD influences the expression
and localization of TJ proteins [120–122]. The extracellular matrix and TJ proteins are substrates of
MMPs, whose activity is also increased in AD and after ischemic injury, which results in lower TJ
proteins [123]. Data concerning TJ changes in Alzheimer’s, Parkinson’s and Huntington’s diseases,
as well as schizophrenia are summarized in Table 3.
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Table 3. BBB function and junctional proteins in age related disorders, neurodegenerative diseases.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
Triple-transgenic mice (3 ×
Tg-AD), 10–11 vs. 4 month old
no change in [3H]-inulin
and [14C]-sucrose uptake
Age dependent
reduction in
cerebrovascular volume,
thickened basal
membrane
Bourasset et al.,
2009, Mehta et al.,
2013 [124]
18–20 month old 3 × Tg-AD vs.
wild type mice
no change in [3H]-inulin
and [14C]-sucrose uptake
decreased uptake of
passively diffusing markers:
[3H] diazepam and [3H]
propranolol in AD mice
thickened basal
membrane
rat brain microvessel
endothelial cells +Aβ1-42 for
24–72 h, immunofluorescence
disrupted
localization after
24 h, increased
fluorescence of
Claudin 5 and 1.
no change in localization. Decreased
fluorescence at 24 hours.
ZO-2 diffuse
localization. ZO-2
increased fluorescence
at 24 h and decreased
at 72 h.
Marco and Skaper
2006 [120]
capillary cerebral amyloid
angiopathy (capCAA) patient
brain sections
loss of protein in capillaries with amyloid β deposits Carrano et al.,
2011, 2012
[125,126]hCMEC/D3 cell culture +
Aβ1-42 for 24 h dose dependent, ROS mediated decrease of mRNA for both
ARPE-19 cell culture +
oligomeric Aβ1-42
disrupted membrane staining,
significantly decreased mRNA
increased 40 kDa
FITC-dextran permeability Bruban et al., 2009
[127]subretinal Aβ1-42 injection in
C57BL/6 J mice
Similarly disrupted membrane staining of both in young, adult
and aged mice.
bEnd.3+Aβ1-42 decreased protein level
decreased protein
levels rescued by
inhibition of either
RAGE, calcineurin or
MMP
increased 40 kDa
FITC-dextran permeability
rescued by inhibition of
calcineurin or MMP
Kook et al., 2012
[128]
8 months old transgenic mice
with five familial AD mutations
(5XFAD) compared to wild type
TJ cross section length significantly decreased, by transmission electronmicroscopy
RAGE expression was
increased in brain
capillaries
bEnd.3
Oligomeric, but not monomeric or fibrillar Aβ1-42 dose dependently decreased
protein levels. Protein levels were rescued by silencing RAGE with siRNA or
blocking RAGE with a polyclonal antibody.
Wan et al., 2015
[129]
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Table 3. Cont.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
bEnd.3 + oligomeric Aβ1–42 decreased protein levels and increased permeability were rescued by EGb761 in a dose dependent manner
Aβ1–42-Oligo induced
expression of MMP-2
and MMP-9 was
rescued by blocking
RAGE via antibody.
Wan, Cao, et al.,
2014 [130]
bEnd.3 cells+ Aβ1-42 and
isolated capillaries from 5XFAD
mice
exogenous
ANXA1 rescued
Aβ1-42 induced
decrease in protein
levels by blocking
Rho-ROCK
signaling
exogenous ANXA1
rescued Aβ1-42
induced decrease in
protein levels by
blocking Rho-ROCK
signaling
Park et al., 2017
[131]
APOE4 transgene expressing
Apoe-/- mice
protein levels were decreased dependent on the pericytic cyclophilin A/NF-κB/MMP9
dependent pathway Bell et al., 2010 [54]
bEnd.3, CD-1 or PARP-1 KO
mouse primary glial culture
+Aβ1–42
endothelial protein expression reduced by activated microglia
was rescued by PARP inhibition.
Mehrabadi et al.,
2017 [132]
MPTP mouse model +caffeine MPTP treated animals showed decreased protein levels, whichwas rescued by caffeine.
Caffeine rescued MPTP
induced Evans blue leakage
in striatum.
Caffeine blocked
MPTP-induced
increases in MMP9
activity
Chen et al., 2008
[133]
MPTP mouse model +trehalose immunofluorescent signal was greatly diminished in MPTPanimals, which was rescued by trehalose.
Sarkar et al., 2014
[134]
unilateral striatal 6OHDA
injection in rats
FITC-albumin or
horseradish peroxidase
leakage in striatum and
substantia nigra in response
to 6OHDA
Carvey et al., 2005
[135]
unilateral striatal 6OHDA
injection in rats
immunohistochemistry
signal decreased protein levels decreased for both
Huang et al., 2016
[136]
hCMEC/D3 (co-cultured with
mouse primary astrocytes) +
preformed α-synuclein fibrils
decreased protein levels Kuan et al., 2016[137]
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Table 3. Cont.
Experimental System Claudin 5 Occludin ZO-1 Permeability Other Authors
Parkinson’s Disease patient
tissue sections compared to age
matched and deep brain
stimulated patient tissue
decreased immunofluorescent staining compared to control, rescued by deep brain
stimulation. IgG extravasation
Pienaar et al., 2015
[138]
Parkinson’s disease patient
tissue sections blood extravasation
Gray and Woulfe
2015 [139]
Huntington’s disease patient
putamen samples compared to
control
decreased protein levels
extravascular fibrin
deposition., increased
leakage in caudate and
putamen by DCE MRI
abnormal vessel
morphology Drouin-Ouellet et
al., 2015 [140]
and R6/2 mouse model, striatal
samples decreased protein levels
increased pinocytic activity
and increased albumin
extravasation
morphological changes
in vessel walls
iPSC derived brain
microvascular endothelial cells
from HD patients
miss-localization
to the cytoplasm decreased TEER
Lim et al., 2017
[141]
schizophrenic patient brain
tissue
discontinuous
localization
anti-psychotic medications dose dependently increased
claudin 5 expression
Greene et al., 2018.
[142]
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Similar to data on permeability in the aging brain, the BBB permeability data of AD patients was
heterogeneous. This could partly be ascribed to difficulties in separating different types of dementia
and co-morbidities confounding results. In a meta analysis by Farrall and Wardlaw some results show
increased BBB permeability in AD compared to controls but the permeability increase is higher and
more clear cut for vascular dementia and mixed dementias compared to AD [48]. Murine models of
AD allow for more precise control over experiments and make it possible to concentrate on separate
aspects of the disease; however, available results are still conflicting. A number of studies showed
that the paracellular route is unaffected in murine models of AD. There was a substantially decreased
occludin expression in APP/PS1 mice AD model compared to wild-type controls [143]. In some cases,
when using an APP/PS1 mouse model there was an unaltered BBB permeability to 131I-albumin [144]
and to sodium fluorescein [145]. Even though earlier work showed small localized disruption in
Senescence Accelerated Mouse-Prone 8 (SAMP8), no global BBB permeability change was observed
when comparing 12 and 4 months old animals [101]. Comparing 11 and 4 months old 3 × Tg-AD mice
(triple transgenic mice for familial Alzheimer’s disease mutations), Bourasset et al. found no changes
in the distribution of vascular space markers 3H-inulin and 14C-sucrose, but found a global reduction
in cerebrovascular volume that was most significant in the hippocampus [124]. In a comparison of
18–20 month old 3×Tg-AD and wild type mice researchers also did not find changes in 3H-inulin and
14C-sucrose uptake, while the uptake of passively diffusing markers 3H-diazepam and 3H-propranolol
was less in AD mice [146]. These results suggest that in murine AD models global BBB breakdown is
not detectable and research probably should focus on local barrier disruption, as data from multiple
research groups point to the importance of cerebral amyloid angiopathy in AD and there is ample
amount of research revealing the molecular mechanisms behind it.
Regarding TJ proteins in post-mortem human brain, a dramatic loss of claudin 5, occludin and
ZO-1 was demonstrated in Aβ-laden capillaries surrounded by NADPH oxidase-2 (NOX-2)-positive
activated microglia. Further results show that Aβ is toxic to endothelial cells in the human brain via
binding to the receptor for advanced glycation end-products (RAGE) and induction of ROS production,
which ultimately leads to disruption of TJs and loss of BBB integrity [125,126]. In a model of age-related
macular degeneration, increased formation of ROS was found after administration of the oligomeric
form of Aβ1–42 to retinal pigmented epithelial cells [127], which was accompanied by a decrease in
the expression of occludin. The Aβ1-42 peptide accumulation around brain microvessels was found to
be mediated by transport via RAGE in 5XFAD mice, increasing permeability, disrupting claudin 5,
ZO-1 and occludin. This MMP and Ca2+-calcineurin dependent BBB disruption could be prevented
in bEnd.3 cells by neutralizing antibodies against RAGE [128], small interfering RNA knockdown of
RAGE [129] or Ginkgo biloba extract EGb761 [130].
An in vitro study on Aβ1-42-treated bEnd.3 cells showed that AnnexinA1 (ANXA1), an
anti-inflammatory messenger, significantly rescued the expression of claudin 5 and ZO-1 and barrier
function in Aβ1-42 -treated bEnd.3 cells. Aβ1–42 reduced ANXA1 bEnd.3 cells, and also had reduced
expression in capillaries of 5XFAD mice, and the human serum of patients with AD. ANXA1 acted
via the inhibition of RhoA-ROCK signaling. In co-culture experiments, pericyte secreted ANXA1
attenuated the Aβ1–42-induced disruption of the tight junction [131].
Pericytes influence the BBB by promoting TJ protein expression in endothelial cells [54] and
helping the alignment of TJs [147]. It has also been shown that a loss of pericytes plays a role in AD
development and is followed by a decreased expression of TJ proteins [148,149].
The strongest genetic risk factor for late onset AD is Apolipoprotein E4 (ApoE4). ApoE4 and its
receptors are expressed throughout the NVU and are linked to many aspects of cerebrovascular
dysfunction [150,151]. The molecular mechanisms of ApoE4 mediated neurovascular injury
demonstrate how the coordinated effort of multiple cell types maintains a functional NVU. Bell et al.
revealed using multiple transgenic mice that the ApoE induced degradation of TJ proteins claudin
5, ZO-1 and occludin and basal membrane protein collagen IV is the result of an intercellular
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communication error. ApoE4 secreted by astrocytes is unable to bind LRP1 on pericytes and thus does
not block the pericytic cyclophilin A/NF-κB/MMP9 pathway, which results in vascular dysfunction [152].
Soluble Aβ is also known to induce secretion of proinflammatory cytokines (TNF and IL-6) and
chemokines, which stimulate the production of MMP-2 and MMP-9 and it also activates the production
of ROS [153]. Furthermore, experimental data confirms the involvement of all cells of the NVU in
the effect of Aβ. Microglia activated by Aβ treatment shows reduced expression of trophic factors
that are responsible for inflammatory resolution and increased pro inflammatory NO and TNFα
release. This affects both astrocytes and capillary endothelium leading to reduced BBB integrity and
function [132].
AD is also accompanied by tau protein accumulation and hyperphosphorylation, which was
shown to promote BBB dysfunction in AD and other tauopathies [154–156].
4.5. Parkinson’s Disease (PD)
The BBB is also involved in the progression of the second most common neurodegenerative
disorder: Parkinson’s disease (PD). The contribution of BBB disruption to PD is not widely studied
despite the implication of known BBB damaging mechanisms and agents such as oxidative stress
and MMPs in the pathomechanism of the disease [157,158]. Thickened basement membrane in the
cingulate cortex and degeneration of the brain microvasculature in PD was reported by Farkas et al.
and Guan et al. [159,160]. Gray and Woulfe published the first report of BBB disruption evidenced by
blood extravasation in striatal PD tissue in 2015 [139]. Motor function and regional blood flow can be
improved in PD patients by deep brain stimulation [161], which is possibly a result of normalizing
aberrant microvasculature in PD. In a study regarding the effects of deep brain stimulation of the
subthalamic nucleus in PD patients, the decreased immunofluorescence signal of claudin 5, occludin
and ZO-1 of PD samples could be rescued by deep brain stimulation treatments [138]. This is in line
with multiple studies using experimental parkinsonism models. Significant decrease was detected
in the amount of occludin in the striatum, which was associated with increased BBB leakage, in the
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model. Increased striatal MMP-9
activity was also detected in the MPTP model with a possible role in TJ opening [133,134]. Increased
permeability of the BBB was also observed in the striatum in rats after treatment with unilateral
injections with 6-Hydroxydopamine (6OHDA) [135] that leads to downregulation of occludin [136].
Similar to amyloid oligomers in AD the Lewy body component α-synuclein was found to damage
BBB. An in vitro study showed that preformed α-synuclein fibrils lead to a decrease in the expression
of occludin and ZO-1, but not tricellulin or marveld3, in human brain microvascular endothelial
cells [137].
4.6. Huntington’s Disease (HD)
Huntington’s disease (HD) is a dominantly inherited autosomal neurodegenerative disorder that
is not usually considered aging related as it is typically diagnosed at the age of 40, and the onset of the
disease can vary from earlier than ten to over eighty years of age. However, recent research indicates
that epigenetic age acceleration in specific brain regions is associated with HD [162].
Recently, morphological changes of blood vessels and BBB leakage in the caudate and putamen
were observed in HD patients using magnetic resonance imaging. In putamen samples of HD patients
and in striatal samples of the HD model R6/2 mice, occludin and claudin 5 protein levels were
decreased and evidence of increased BBB permeability was found [140]. More recently, these results
were expanded in induced pluripotent stemm cell (iPSC) derived brain microvascular endothelial
cells. While in this system no significant changes in TJ protein levels were observed, claudin 5 was
found to mislocalize to the cytoplasm of cells derived from HD patients; however, trans endothelial
electric resistance (TEER) and MDR1 function was significantly decreased compared to control cell
lines. Some of the changes in cell lines derived from HD patients could be attributed to aberrant Wnt
signaling [141].
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4.7. Schizophrenia
Some aspects of schizophrenia raise the possibility that accelerated aging of the brain can be
responsible for some of its symptoms [163]. Individuals with the chromosomal abnormality: 22q11
deletion syndrome (22q11DS) have an increased risk of developing schizophrenia, in fact it occurs in
30% of such individuals. Interestingly, 22q11DS are haploinsufficient for claudin 5. Recent experiments
on AAV mediated claudin 5 suppression in mice and inducible claudin 5 knockdown uncovered focal
BBB breakdown and behavioral changes. Anti-psychotic medications were found to dose dependently
increase claudin 5 expression. Furthermore post mortem analysis of schizophrenic brains revealed
aberrant, discontinuous expression of claudin 5 [142].
5. Closing Remarks
Aging comes with the deterioration of all bodily functions of which the loss of cognitive function
is possibly the most serious in our heavily information dependent society. With the building evidence
that dysfunction of the microvasculature is not just coincident but is part of the underlying mechanisms
of aging and associated neurovascular and neurological disorders, new therapeutic possibilities are
opened. The significant heterogeneity of BBB disruption data in studies using aging postmortem brain
tissue suggests that more data is necessary to clearly understand the role of BBB disruption and to see
whether it is a symptom or a cause [48]. It is not surprising that human BBB data before the mid-1990s
is mainly regarding permeability; however, even since the discovery of occludin, zonula occludens
proteins and claudins, BBB TJ data in the aging brain is scarce and this deficit is just partly made up for
by data from aging associated disorders. Furthermore many studies disregard that claudin 5, occludin
or ZO1 does not constitute the paracellular barrier by itself and all three should be studied along
with permeability to different molecular size tracers at the same time to get a picture of barrier status.
Worsening the situation is that the reliability of existing TJ data has been questioned recently [35].
Thus further comprehensive BBB TJ and permeability studies are needed in the field of aging and aging
associated disorders. Another focus needs to be the study of both classical and novel intercellular
communication pathways between brain capillary endothelium, pericytes, astrocytes, microglia and
neurons as the concerted activity of all these cell types is necessary for proper neural function. We are
just beginning to understand the depth and mechanisms of intercellular information exchange that
makes the NVU a functional unit. The knowledge of how the interdependent functions of the cell types
constituting the NVU are affected by the process of aging can lead to the alleviation of age related
impairments and a better quality of life.
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Abbreviations
BBB blood–brain barrier
TJ tight-junction
CNS central nervous system
NVU neurovascular unit
CEC Cerebral endothelial cells
ZO-1 zonula occludens 1 protein
MCAO middle cerebral artery occlusion
Aβ amyloid-beta protein
Aβ1-42 amyloid-beta peptide containing amino acids 1-42
AD Alzheimer’s disease
MMP matrix metalloproteinase
PD Parkinson’s disease
HD Huntington’s disease
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